Please login to the form below

Not currently logged in
Email:
Password:

acute myeloid leukaemia

This page shows the latest acute myeloid leukaemia news and features for those working in and with pharma, biotech and healthcare.

Dutch biotech Argenx claims $1.8bn licensing deal with J&J

Dutch biotech Argenx claims $1.8bn licensing deal with J&J

The deal centres on cusatuzumab (ARGX-110), a CD70-targeting antibody that is being developed for the treatment of acute myeloid leukaemia (AML), myelodysplastic syndrome (MDS) and other haematological cancers and

Latest news

  • Amgen’s BCMA drug on course to challenge CAR-Ts in myeloma Amgen’s BCMA drug on course to challenge CAR-Ts in myeloma

    congress. In a 40-patient study involving patients with acute myeloid leukaemia who had undergone several prior lines of treatment, AMG 330 achieved complete responses in two patients, plus two complete

  • Astellas, Catalyst approvals set up record year for FDA approvals Astellas, Catalyst approvals set up record year for FDA approvals

    The approvals of Astellas’ FLT3 inhibitor Xospata (gilteritinib) for acute myeloid leukaemia and Catalyst Pharmaceuticals’ Firdapse (amifampridine) for rare autoimmune disease Lambert-Eaton Myasthenic Syndrome (LEMS), already put the number for

  • Pfizer gets first FDA nod for hedgehog inhibitor in AML Pfizer gets first FDA nod for hedgehog inhibitor in AML

    Daurismo cleared for those too frail for chemo. Pfizer has added to a run of new product approvals for acute myeloid leukaemia (AML) with an FDA nod for Daurismo, the first ... indications such as myelodysplastic syndrome (MDS), acute lymphoblastic

  • AZ swells immuno-oncology pipeline with Innate deal AZ swells immuno-oncology pipeline with Innate deal

    There’s also some money flowing in the other direction, as Innate is licensing US co-commercial rights to Lumoxiti (moxetumomab pasudotox) - AZ’s recently-approved hairy cell leukaemia therapy - in ... myeloid leukaemia.

  • AZ nabs US approval for new leukaemia drug Lumoxiti AZ nabs US approval for new leukaemia drug Lumoxiti

    Lumoxiti (moxetumomab pasudotox-tdfk) is the first new treatment for this type of leukaemia in 20 years, according to AZ. ... The approval is also remarkable because it adds to the small stable of ADCs that have been approved for marketing, along with

More from news
Approximately 2 fully matching, plus 87 partially matching documents found.

Latest Intelligence

  • Digital disruption Digital disruption

    Initially AZ and Microsoft have focused acute myeloid leukaemia (AML), simulating experiments to predict how drug combinations might be used to overcome resistance to drugs that target cell signalling in AML,

  • Deal Watch January 2017 Deal Watch January 2017

    With an enterprise value of $5.2bn this acquisition brings access to Iclusig (ponatinib), approved for chronic myeloid leukaemia (CML) and acute lymphoblastic leukaemia (ALL), as well as brigatinib in phase ... 1, 000. CoLucid. Lilly. Company acquisition.

  • Deal Watch December 2016 Deal Watch December 2016

    511. BioInvent (Sweden). Pfizer (US). Research collaboration. Development of immuno-regulatory antibodies targeting tumour-associated myeloid cells. ... Commercial milestones of up to $150m. Lead product has completed phase II in acute myeloid leukaemia.

  • Deal Watch August 2016 Deal Watch August 2016

    540. MEI Pharma (US). Helsinn (CH). Licence. Pracinostat, phase III-ready HDAC inhibitor for treatment of acute myeloid leukaemia. ... 151. Valeant (US). Pharming (NL). Asset acquisition North America. Ruconest (recombinant human C1 esterase inhibitor)

  • Deal Watch June 2016 Deal Watch June 2016

    Paying $150m upfront Novartis gains access to XmAb14045 being developed for acute myeloid leukaemia (AML) and XmAb13676 in development for B-cell malignancies. ... on B-cell tumor cells, including chronic lymphocytic leukaemia (CLL) and non-Hodgkin

More from intelligence
Approximately 0 fully matching, plus 15 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics